Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

por Miles, D W, de Haas, S L, Dirix, L Y, Romieu, G, Chan, A, Pivot, X, Tomczak, P, Provencher, L, Cortés, J, Delmar, P R, Scherer, S J
Publicado 2013

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III stu...

por de Haas, Sanne L., Slamon, Dennis J., Martin, Miguel, Press, Michael F., Lewis, Gail D., Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A.
Publicado 2023

Organisational design for an integrated oncological department

por Meiss-de Haas, Ch.L., Falkmann, H., Douma, J., van Gassel, J.G., Peters, W.G., van Mierlo, R., van Turnhout, J.M., Verhagen, C.A.H.H.V.M., Schrijvers, A.J.P.
Publicado 2001